{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:19:41Z","timestamp":1787861981048,"version":"build-2784847793"},"reference-count":93,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001845","name":"Science for Equity, Empowerment and Development Division","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001845","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017603","name":"UPES","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.micpath.2025.108115","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T23:28:38Z","timestamp":1760570918000},"page":"108115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Clinical perspective of multiple drug resistance tuberculosis: An overview"],"prefix":"10.1016","volume":"209","author":[{"given":"Arpit","family":"Raj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikrant","family":"Abbot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2875-2119","authenticated-orcid":false,"given":"Kapil","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1017\/S0021932009990538","article-title":"The impact of exposure to mass media campaigns and social support on levels and trends of HIV-related stigma and discrimination in Nigeria: tools for enhancing effective HIV prevention programmes","volume":"42","author":"Fakolade","year":"2010","journal-title":"J. Biosoc. Sci."},{"key":"10.1016\/j.micpath.2025.108115_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nrmicro2797","article-title":"Global tuberculosis control: lessons learnt and future prospects","volume":"10","author":"Lienhardt","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.micpath.2025.108115_bib3","article-title":"Pattern of drug resistance and risk factors associated with development of drug-resistant Mycobacterium tuberculosis in Pakistan","volume":"11","author":"Irfan","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.micpath.2025.108115_bib4","article-title":"Comparison of treatment outcomes of new smear-positive pulmonary tuberculosis patients by HIV and antiretroviral status in a TB\/HIV clinic","volume":"8","author":"Tweya","year":"2013","journal-title":"Malawi. PloS One."},{"key":"10.1016\/j.micpath.2025.108115_bib5","first-page":"3158","volume":"2","author":"Fitzgerald","year":"2010"},{"key":"10.1016\/j.micpath.2025.108115_bib6","article-title":"Nanocarriers for tuberculosis therapy: design of safe and effective drug delivery strategies to overcome the therapeutic challenges","volume":"67","author":"Sarkar","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0147529","article-title":"Pattern of drug resistance and risk factors associated with development of drug-resistant Mycobacterium tuberculosis in Pakistan","volume":"11","author":"Ullah","year":"2016","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.micpath.2025.108115_bib8","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1473-3099(13)70015-X","article-title":"Tuberculosis comorbidity with communicable and non-communicable diseases: integrating health services and control efforts","volume":"13","author":"Marais","year":"2013","journal-title":"Lancet Infect. Dis."},{"issue":"7","key":"10.1016\/j.micpath.2025.108115_bib9","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1136\/oem.55.7.496","article-title":"Risk of pulmonary tuberculosis relative to silicosis and exposure to silica dust in South African gold miners","volume":"55","author":"Hnizdo","year":"1998","journal-title":"Occup. Environ. Med."},{"key":"10.1016\/j.micpath.2025.108115_bib10","series-title":"The Risk of Tuberculosis Related to Tumour Necrosis Factor Antagonist Therapies: a TBNET Consensus Statement","first-page":"1185","author":"Solovic","year":"2010"},{"issue":"15","key":"10.1016\/j.micpath.2025.108115_bib11","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1097\/QAD.0000000000000802","article-title":"Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis","volume":"29","author":"Gupta","year":"2015","journal-title":"AIDS"},{"key":"10.1016\/j.micpath.2025.108115_bib12","series-title":"Nanotechnology-Based Targeted Drug Delivery Systems for Lung Cancer","first-page":"1","article-title":"An overview of the anatomy and physiology of the lung","author":"Aung","year":"2019"},{"key":"10.1016\/j.micpath.2025.108115_bib13","first-page":"20","article-title":"Anatomy and histology of the lung","volume":"1","author":"Tomashefski","year":"2008"},{"key":"10.1016\/j.micpath.2025.108115_bib14","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s00418-018-1747-9","article-title":"The micromechanics of lung alveoli: structure and function of surfactant and tissue components","volume":"150","author":"Knudsen","year":"2018","journal-title":"Histochem. Cell Biol."},{"key":"10.1016\/j.micpath.2025.108115_bib15","first-page":"529","article-title":"Human physiology","volume":"12","author":"Fox","year":"2010","journal-title":"Mc Graw Hill"},{"key":"10.1016\/j.micpath.2025.108115_bib16","first-page":"445","volume":"9","author":"Sherwood","year":"2014"},{"key":"10.1016\/j.micpath.2025.108115_bib17","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/nn.2622","article-title":"Hindbrain interneurons and axon guidance signaling critical for breathing","volume":"13","author":"Bouvier","year":"2010","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.micpath.2025.108115_bib18","first-page":"752","article-title":"The first clinical trial of streptomycin in human tuberculosis","volume":"71","author":"Pfuetze","year":"1955","journal-title":"Am. Rev. Tubercul."},{"key":"10.1016\/j.micpath.2025.108115_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1515\/ejnm-2014-0019","article-title":"Overcoming the pulmonary barrier: new insights to improve the efficiency of inhaled therapeutics","volume":"6","author":"Murgia","year":"2014","journal-title":"Eur. J. Nanomed."},{"key":"10.1016\/j.micpath.2025.108115_bib20","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","volume":"11","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.micpath.2025.108115_bib21","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0065-2571(00)00013-3","article-title":"The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting","volume":"41","author":"Maeda","year":"2001","journal-title":"Adv. Enzym. Regul."},{"key":"10.1016\/j.micpath.2025.108115_bib22","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1146\/annurev.bioeng.8.061505.095735","article-title":"Recent approaches to intracellular delivery of drugs and DNA and organelle targeting","volume":"8","author":"Torchilin","year":"2006","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.micpath.2025.108115_bib23","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.2147\/IJN.S364634","article-title":"Innovative therapeutic approaches based on nanotechnology for the treatment and management of tuberculosis","volume":"31","author":"Kia","year":"2023","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.micpath.2025.108115_bib24","first-page":"1342","article-title":"Tuberculosis","volume":"18","author":"Raviglione","year":"2012"},{"key":"10.1016\/j.micpath.2025.108115_bib25","series-title":"The Normal Lung: the Basis for Diagnosis and Treatment of Pulmonary Disease","first-page":"344","author":"Murray","year":"1986"},{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib26","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1084\/jem.134.3.713","article-title":"Response of cultured macrophages to Mycobacterium tuberculosis, with observations on fusion of lysosomes with phagosomes","volume":"134","author":"Armstrong","year":"1971","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3181\/00379727-145-37771","article-title":"Failure of passive serum transfer of immunity against aerogenic tuberculosis in rabbits","volume":"145","author":"Reggiardo","year":"1974","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.micpath.2025.108115_bib28","doi-asserted-by":"crossref","first-page":"94","DOI":"10.2174\/156652409787581655","article-title":"Pathogenesis of central nervous system tuberculosis","volume":"9","author":"Be","year":"2009","journal-title":"Curr. Mol. Med."},{"issue":"6","key":"10.1016\/j.micpath.2025.108115_bib29","first-page":"981","article-title":"Tuberculous pleural effusions: advances and controversies","volume":"7","author":"Vorster","year":"2015","journal-title":"J. Theat. Drama"},{"key":"10.1016\/j.micpath.2025.108115_bib30","first-page":"942","volume":"10","author":"Ferrer","year":"1997","journal-title":"Pleural Tuberculosis. Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib31","first-page":"230","article-title":"Clinical investigation of cavitary tuberculosis and tuberculous pneumonia. Korean","volume":"21","author":"Lee","year":"2006","journal-title":"J. Intern. Med."},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib32","doi-asserted-by":"crossref","first-page":"153","DOI":"10.4046\/trd.2014.76.4.153","article-title":"Tuberculous pleurisy: an update","volume":"76","author":"Jeon","year":"2014","journal-title":"Tuberc. Respir. Dis."},{"key":"10.1016\/j.micpath.2025.108115_bib33","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/TCRM.S29179","article-title":"Diagnosis and management of miliary tuberculosis: current state and future perspectives","volume":"9","author":"Ray","year":"2013","journal-title":"Therapeut. Clin. Risk Manag."},{"issue":"6","key":"10.1016\/j.micpath.2025.108115_bib34","first-page":"374","article-title":"Effects of laryngeal tuberculosis on vocal fold functions: case report","volume":"25","author":"\u00d6z\u00fcdogru","year":"2005","journal-title":"Acta Otorhinolaryngol. Ital."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib35","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4269\/ajtmh.2013.12-0413","article-title":"Renal tuberculosis in the modern era","volume":"88","author":"Daher","year":"2013","journal-title":"Am. J. Trop. Med. Hyg."},{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib36","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1212\/CPJ.0000000000000023","article-title":"Tuberculous meningitis: diagnostic and therapeutic challenges","volume":"4","author":"Chin","year":"2014","journal-title":"Neurol. Clin. Pract."},{"issue":"23","key":"10.1016\/j.micpath.2025.108115_bib37","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1161\/CIRCULATIONAHA.105.543066","article-title":"Tuberculous pericarditis","volume":"112","author":"Mayosi","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.micpath.2025.108115_bib38","series-title":"Tropical Infectious Diseases","first-page":"394","article-title":"Tuberculosis and atypical mycobacterial infections","author":"Johnson","year":"2006"},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF03351067","article-title":"The endocrinology of adrenal tuberculosis: the effects of tuberculosis on the hypothalamo-pituitary-adrenal axis and adrenocortical function","volume":"27","author":"Kelestimur","year":"2004","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.micpath.2025.108115_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109397","article-title":"Multidrug resistant tuberculosis-diagnostic challenges and its conquering by nanotechnology approach-An overview","volume":"337","author":"Muthukrishnan","year":"2021","journal-title":"Chem. Biol. Interact."},{"issue":"5","key":"10.1016\/j.micpath.2025.108115_bib41","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a017822","article-title":"Tuberculosis treatment and drug regimens","volume":"5","author":"Sotgiu","year":"2015","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.micpath.2025.108115_bib42","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1440-1843.2010.01738.x","article-title":"Drug-resistant tuberculosis: past, present, future","volume":"15","author":"Chiang","year":"2010","journal-title":"Respirology"},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib43","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1021\/ar200094a","article-title":"Supramolecular nanodevices: from design validation to theranostic nanomedicine","volume":"44","author":"Cabral","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.micpath.2025.108115_bib44","first-page":"796","article-title":"Role of individual drugs in the chemotherapy of tuberculosis","volume":"4","author":"Mitchison","year":"2000","journal-title":"Int. J. Tubercul. Lung Dis."},{"issue":"2","key":"10.1016\/j.micpath.2025.108115_bib45","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expet Opin. Drug Saf."},{"key":"10.1016\/j.micpath.2025.108115_bib46","series-title":"Clinical Tuberculosis","year":"2020"},{"key":"10.1016\/j.micpath.2025.108115_bib47","first-page":"66","article-title":"Chapter 5: treatment of tuberculosis disease, Canadian journal of respiratory, critical care, and","volume":"6","author":"James","year":"2022","journal-title":"Sleep Med."},{"key":"10.1016\/j.micpath.2025.108115_bib48","first-page":"32","article-title":"Chapter 5: recent developments in the study of pyrazinamide: an update","volume":"40","author":"Mitchison","year":"2011"},{"key":"10.1016\/j.micpath.2025.108115_bib49","series-title":"A Clinician's Guide to Tuberculosis","first-page":"448","author":"Iseman","year":"2000"},{"key":"10.1016\/j.micpath.2025.108115_bib50","series-title":"Drug Susceptibility in the Chemotherapy of Mycobacterial Infections","first-page":"123","year":"1991"},{"key":"10.1016\/j.micpath.2025.108115_bib51","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.rppnen.2017.10.009","article-title":"New drugs and perspectives for new anti-tuberculosis regimens","volume":"24","author":"Tiberi","year":"2018","journal-title":"Pulmonology"},{"issue":"2","key":"10.1016\/j.micpath.2025.108115_bib52","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1517\/14740338.5.2.231","article-title":"Adverse reactions to first-line antituberculosis drugs","volume":"5","author":"Forget","year":"2006","journal-title":"Expet Opin. Drug Saf."},{"issue":"18","key":"10.1016\/j.micpath.2025.108115_bib53","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"NEJM"},{"key":"10.1016\/j.micpath.2025.108115_bib54","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/resp.13345","article-title":"New drugs and regimens for tuberculosis","volume":"23","author":"Chang","year":"2018","journal-title":"Respirology"},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib55","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1021\/acsinfecdis.5b00127","article-title":"Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB\/FeJ mice","volume":"2","author":"Irwin","year":"2016","journal-title":"ACS Infect. Dis."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib56","first-page":"93","article-title":"Treatment of drug-resistant tuberculosis. An official ATS\/CDC\/ERS\/IDSA clinical practice guideline","volume":"200","author":"Nahid","year":"2019","journal-title":"AJRCCM"},{"issue":"6","key":"10.1016\/j.micpath.2025.108115_bib57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/mBio.01741-15","article-title":"Preclinical evaluations to identify optimal linezolid regimens for tuberculosis therapy","volume":"6","author":"Brown","year":"2015","journal-title":"mBio"},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib58","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002773","article-title":"Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: a mechanistic model and tool for regimen and dose optimization","volume":"16","author":"Strydom","year":"2019","journal-title":"PLoS Med."},{"issue":"7","key":"10.1016\/j.micpath.2025.108115_bib59","doi-asserted-by":"crossref","first-page":"e147","DOI":"10.1093\/cid\/ciw376","article-title":"Official american thoracic society\/centers for disease control and prevention\/infectious diseases society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.micpath.2025.108115_bib60","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.ccm.2019.08.001","article-title":"New drugs for the treatment of tuberculosis","volume":"40","author":"Ignatius","year":"2019","journal-title":"Clin. Chest. Med."},{"key":"10.1016\/j.micpath.2025.108115_bib61","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.717045","article-title":"Mechanism of action, resistance, synergism, and clinical implications of delamanid against multidrug-resistant mycobacterium tuberculosis","volume":"12","author":"Khoshnood","year":"2021","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib62","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1080\/17425255.2021.1836158","article-title":"Therapeutic drug monitoring in patients with tuberculosis and concurrent medical problems","volume":"17","author":"M\u00e4rtson","year":"2021","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"issue":"2","key":"10.1016\/j.micpath.2025.108115_bib63","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s13353-015-0309-2","article-title":"Genetic control of bacterial biofilms","volume":"57","author":"Wolska","year":"2016","journal-title":"J. Appl. Genet."},{"key":"10.1016\/j.micpath.2025.108115_bib64","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1146\/annurev.genet.40.110405.090423","article-title":"Mechanisms of cyclic-di-GMP signaling in bacteria","volume":"40","author":"Jenal","year":"2006","journal-title":"Annu. Rev. Genet."},{"key":"10.1016\/j.micpath.2025.108115_bib65","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int. J. Nanomed."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib66","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1021\/acs.molpharmaceut.1c00491","article-title":"Nanoparticle-based drug delivery system: the magic bullet for the treatment of chronic pulmonary diseases","volume":"18","author":"Pramanik","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.micpath.2025.108115_bib67","doi-asserted-by":"crossref","first-page":"4414","DOI":"10.3390\/ijms12074414","article-title":"Isoniazid proliposome powders for inhalation-preparation, characterization and cell culture studies","volume":"12","author":"Rojanarat","year":"2011","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib68","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1517\/17425247.1.1.67","article-title":"Dry powder inhalers for pulmonary drug delivery","volume":"1","author":"Frijlink","year":"2004","journal-title":"Expet Opin. Drug Deliv."},{"key":"10.1016\/j.micpath.2025.108115_bib69","article-title":"Nanocarriers for tuberculosis therapy: design of safe and effective drug delivery strategies to overcome the therapeutic challenges","volume":"67","author":"Sarkar","year":"2021","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.micpath.2025.108115_bib70","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1590\/s1806-37562017000000443","article-title":"Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs","volume":"44","author":"Silva","year":"2018","journal-title":"J. Bras. Pneumol."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib71","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.3390\/molecules22101560","article-title":"Novel anti-tuberculosis nano-delivery formulation of ethambutol with graphene oxide","volume":"22","author":"Saifullah","year":"2017","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib72","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.13005\/ojc\/330358","article-title":"Synthesis of mixed metal oxides nano-colloidal particles and investigation of the cytotoxicity effects on the human pulmonary cell lines: a prospective approach in anti-tuberculosis inhaled nanoparticles","volume":"33","author":"Jafari","year":"2017","journal-title":"Orient. J. Chem."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib73","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1021\/nn4044047","article-title":"Toxicity mechanisms in Escherichia coli vary for silver nanoparticles and differ from ionic silver","volume":"8","author":"Ivask","year":"2014","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/pharmaceutics13010079","article-title":"Pulmonary targeting of inhalable moxifloxacin microspheres for effective management of tuberculosis","volume":"13","author":"Vishwa","year":"2021","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib75","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.ejpb.2007.04.005","article-title":"Liposomes for drug delivery to the lungs by nebulization","volume":"67","author":"Zaru","year":"2007","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.micpath.2025.108115_bib76","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1208\/s12249-019-1334-y","article-title":"Ethambutol-loaded solid lipid nanoparticles as dry powder inhalable formulation for tuberculosis therapy","volume":"20","author":"Nemati","year":"2019","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.micpath.2025.108115_bib77","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.micpath.2017.07.010","article-title":"Bactericidal impact of Ag, ZnO and mixed AgZnO colloidal nanoparticles on H37Rv Mycobacterium tuberculosis phagocytized by THP-1 cell lines","volume":"110","author":"Jafari","year":"2017","journal-title":"Microb. Pathog."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib78","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1021\/acs.bioconjchem.6b00430","article-title":"Gold nanorods as drug delivery vehicles for rifampicin greatly improve the efficacy of combating Mycobacterium tuberculosis with good biocompatibility with the host cells","volume":"27","author":"Ali","year":"2016","journal-title":"Bioconjug. Chem."},{"issue":"3","key":"10.1016\/j.micpath.2025.108115_bib79","doi-asserted-by":"crossref","first-page":"258","DOI":"10.4103\/0250-474X.159602","article-title":"Formulation and characterization of pyrazinamide polymeric nanoparticles for pulmonary tuberculosis: efficiency for alveolar macrophage targeting","volume":"77","author":"Varma","year":"2015","journal-title":"Indian J. Pharmaceut. Sci."},{"key":"10.1016\/j.micpath.2025.108115_bib80","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.2147\/IJN.S251524","article-title":"The effects study of isoniazid conjugated multi-wall carbon nanotubes nanofluid on Mycobacterium tuberculosis","volume":"15","author":"Zomorodbakhsh","year":"2020","journal-title":"Int. J. Nanomed."},{"issue":"4","key":"10.1016\/j.micpath.2025.108115_bib81","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1128\/AAC.01471-09","article-title":"Dry powder PA-824 aerosols for treatment of tuberculosis in Guinea pigs","volume":"54","author":"Garcia-Contreras","year":"2010","journal-title":"AAC"},{"key":"10.1016\/j.micpath.2025.108115_bib82","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.carbpol.2019.04.056","article-title":"Dual delivery of tuberculosis drugs via cyclodextrin conjugated curdlan nanoparticles to infected macrophages","volume":"218","author":"Basha","year":"2019","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.micpath.2025.108115_bib83","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.ejps.2018.08.038","article-title":"Chitosan nanoparticles as a promising approach for pulmonary delivery of bedaquiline","volume":"124","author":"Rawal","year":"2018","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib84","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.3390\/polym11101632","article-title":"Clarithromycin-loaded poly (lactic-co-glycolic acid)(PLGA) nanoparticles for oral administration: effect of polymer molecular weight and surface modification with chitosan on formulation, nanoparticle characterization and antibacterial effects","volume":"11","author":"\u00d6zt\u00fcrk","year":"2019","journal-title":"Polymers"},{"key":"10.1016\/j.micpath.2025.108115_bib85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/microorganisms7080255","article-title":"Adjuvant strategies for more effective tuberculosis vaccine immunity","volume":"7","author":"Stewart","year":"2019","journal-title":"Microorganisms"},{"issue":"13","key":"10.1016\/j.micpath.2025.108115_bib86","doi-asserted-by":"crossref","first-page":"5596","DOI":"10.1073\/pnas.0700869104","article-title":"Genome plasticity of BCG and impact on vaccine efficacy","volume":"104","author":"Brosch","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1","key":"10.1016\/j.micpath.2025.108115_bib87","first-page":"204","article-title":"Prevalence of tuberculosis\/COVID-19 co-infection and factors associated with SARS-CoV-2 infection in pulmonary tuberculosis patients at a respiratory diseases center: a cross-sectional study","volume":"44","author":"Mangamba","year":"2023","journal-title":"Pan African Med. J."},{"key":"10.1016\/j.micpath.2025.108115_bib88","first-page":"338","article-title":"Tuberculosis and coronavirus disease 2019 (COVID-19) from a clinical perspective: a systematic review","volume":"35","author":"Irfani","year":"2020","journal-title":"Medeni Med. J."},{"issue":"10","key":"10.1016\/j.micpath.2025.108115_bib89","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/JCM.01582-19","article-title":"Advances in molecular diagnosis of tuberculosis","volume":"58","author":"MacLean","year":"2020","journal-title":"J. Clin. Microbiol."},{"issue":"6","key":"10.1016\/j.micpath.2025.108115_bib90","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S2213-2600(22)00092-3","article-title":"The intersecting pandemics of tuberculosis and COVID-19: population-level and patient-level impact, clinical presentation, and corrective interventions","volume":"10","author":"Dheda","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.micpath.2025.108115_bib91","first-page":"1","article-title":"Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study","author":"Miller","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.micpath.2025.108115_bib92","series-title":"Global Tuberculosis Report 2024","first-page":"1","year":"2024"},{"key":"10.1016\/j.micpath.2025.108115_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2023.107991","article-title":"Computational insights into potential marine natural products as selective inhibitors of Mycobacterium tuberculosis InhA: a structure-based virtual screening study","volume":"108","author":"Jayaraman","year":"2024","journal-title":"Comput. Biol. Chem."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240102500840X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088240102500840X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T18:00:58Z","timestamp":1763488858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088240102500840X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":93,"alternative-id":["S088240102500840X"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108115","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical perspective of multiple drug resistance tuberculosis: An overview","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2025.108115","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108115"}}